Atherosclerosis
Volume 184, Issue 1 , Pages 8-14 , January 2006

Stabilization of advanced atherosclerosis in low-density lipoprotein receptor-deficient mice by aspirin

  • Tillmann Cyrus

      Affiliations

    • Division of Cardiology, Department of Medicine, Barnes-Jewish Hospital, Washington University School of Medicine in Saint Louis, Room 4402, Steinberg Building, 660 S. Euclid, Campus Box 8086, Saint Louis, MO 63110, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 314 454 8432; fax: +1 314 454 5265.
    • ,
  • Yuemang Yao

      Affiliations

    • The Center for Experimental Therapeutics and Department of Pharmacology, University of Pennsylvania, School of Medicine, Philadelphia, PA, USA
    • ,
  • Liun X. Tung

      Affiliations

    • The Center for Experimental Therapeutics and Department of Pharmacology, University of Pennsylvania, School of Medicine, Philadelphia, PA, USA
    • ,
  • Domenico Praticò

      Affiliations

    • The Center for Experimental Therapeutics and Department of Pharmacology, University of Pennsylvania, School of Medicine, Philadelphia, PA, USA

Received 18 August 2004 ,Accepted 12 October 2004.

References 

  1. Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. Br Med J. 1998;316:1303–1309
  2. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71–86.
  3. Cleland JGF. Preventing atherosclerotic events with aspirin. Br Med J. 2002;324:103–105
  4. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular Events. Arch Intern Med. 2002;162:2197–2202
  5. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventative Services Task Force. Ann Intern Med. 2002;136:161–172
  6. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–126
  7. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104:503–516
  8. Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans. Trends Cardiovasc Med. 2001;11:93–102
  9. Lindahl B, Toss H, Siegbahn A. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary disease. N Engl J Med. 2000;343:1139–1147
  10. Praticò D, Cyrus T, Zhang Z-B, Li H, FitzGerald GA. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low-density lipoprotein receptor knock-out mice. Proc Natl Acad Sci USA. 2001;98:3358–3363
  11. Cyrus T, Sung S, Zhao L, et al. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation. 2002;106:1282–1287
  12. Zieske AW, Malcom GT, Strong JP. Natural history and risk factors of atherosclerosis in children and youth: The PDAY study. Ped Pathol Mol Med. 2002;21:213–237
  13. Praticò D, Cyrus T, Li H, FitzGerald GA. Endogenous biosynthesis of thromboxane and prostacyclin in two distinct murine models of atherosclerosis. Blood. 2000;96:3823–3826
  14. FitzGerald GA, Brash AR, Falardeau P, Oates JA. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest. 1981;68:1272–1276
  15. Lawson JA, Brash AR, Doran J, FitzGerald GA. Measurement of urinary 2,3-dinor-thromboxane B2 and thromboxane B2 using bonded-phase phenylboronic acid colums and capillary gas chromatography—negative-ion chemical ionization mass spectrometry. Anal Biochem. 1985;150:463–470
  16. Cyrus T, Tang LX, Rokach J, FitzGerald GA, Praticò D. Lipid peroxidation and platelet activation in murine atherosclerosis. Circulation. 2001;104:1940–1945
  17. Sukhova GK, Schoenbeck U, Rabkin E. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human plaques. Circulation. 1999;99:2503–2509
  18. Grewe PH, Deneke T, Machraoui A, Barmeyer J, Mueller K-M. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol. 2000;35:157–163
  19. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation. 1999;99:44–52
  20. Anderson PG, Bajaj RK, Baxley WA, Roubin GS. Vascular pathology of balloon-expandable flexible coil stents in humans. J Am Coll Cardiol. 1992;19:272–281
  21. Burleigh ME, Babaev VR, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002;105:1816–1823
  22. Belton OA, Duffy A, Toomey S, Fitzgerald DJ. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation. 2003;108:3017–3023
  23. Moreno PR, Purushothaman R, Fuster V, O’Connor WN. Intimomedial interface damage and adventitial inflammation is increased beneath disrupted atherosclerosis in the aorta. Circulation. 2002;105:2504–2511
  24. Varnava AM, Mills PG, Davies MJ. Relationship between coronary artery remodeling and plaque vulnerability. Circulation. 2002;105:934–939
  25. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient. A call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108:1664–1672

PII: S0021-9150(05)00238-8

doi: 10.1016/j.atherosclerosis.2004.10.047

Atherosclerosis
Volume 184, Issue 1 , Pages 8-14 , January 2006

Article Tools

* Image Usage & Resolution